The North America League 2025 has been shaped. JJ and Co have won the North America Challenger Series 2025 after back-to-back ...

When and where will the data on ARV-393 be presented? Data will be presented at the AACR Annual meeting from April 25-30, 2025, in Chicago, Illinois. What are the benefits of combining ARV-393 ...

2025 in Vienna, Austria. ARV-102 is Arvinas’ investigational PROteolysis TArgeting Chimera (PROTAC) degrader targeting leucine-rich repeat kinase 2 (LRRK2), a multifunctional protein that has be ...

Arvinas, Inc, a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, announced that new preclinical combination data for ARV-393 will be ...

today announced that new preclinical combination data for ARV-393 will be presented at the American Association for Cancer Research® (AACR) Annual meeting, April 25-30, 2025 in Chicago ...

Company to highlight preclinical study of ARV-393, an investigational PROTAC BCL6 degrader, in combination with standard of care therapies NEW HAVEN, Conn., April 21, 2025 (GLOBE NEWSWIRE) -- Arvinas, ...